Tempus ECG-AF vs Us2.v1
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 60/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Tempus ECG-AF is designed for predicting the risk of atrial fibrillation using 12-lead ECG recordings in specific patient populations. In contrast, Us2.v1 offers fully automated diagnostic analysis of echocardiography images, generating comprehensive reports for various cardiac conditions. While both are cardiology AI tools, they utilize different diagnostic modalities and address distinct clinical questions, making them adjacent rather than direct competitors.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
Tempus ECG-AF is designed to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months. Us2.v1 provides fully automated AI software for echocardiography analysis, generating comprehensive structured reports with measurements and disease detection, including automated detection of cardiac amyloidosis and pulmonary hypertension.
Tempus ECG-AF analyzes 12-lead ECG recordings to detect signs associated with new onset Atrial Fibrillation. Us2.v1 performs fully automated analysis of echocardiography images to provide comprehensive cardiac measurements and disease detection.
Tempus ECG-AF is intended for patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery. Us2.v1 is indicated for use in adult patients for general echocardiography analysis and disease detection.
Yes, Tempus ECG-AF has CMS reimbursement available, with CPT codes 0764T and 0765T assigned to APC 5734, and a Medicare rate of $128.90, effective January 1, 2025. Us2.v1 operates on a volume-based pricing model, and specific reimbursement details require contacting the vendor for a quotation.
Tempus ECG-AF supports earlier identification and follow-up for patients at increased risk of new-onset AF, aiding in proactive management. Us2.v1 significantly improves workflow efficiency and diagnostic accuracy by offering zero-click, real-time echocardiography analysis that generates comprehensive reports in seconds.